Paragon Biosciences Emalex Capital: Funding Rounds, Investors & Leadership

About Paragon Biosciences Emalex Capital

Paragon Biosciences Emalex Capital is a private company based in Chicaco, Illinois. It has reported $376,798,366 raised in five offerings on Form D since August 2018.

Funding Rounds (SEC Form D)

First sale	Filed with SEC	Amount sold	Investors	Avg. check	Terms	Filing
May 18, 2022	Nov 4, 2022amended Jul 8, 2025	$270,000,000fully sold	42	$6.4M	EquityRule 506(b)	Form D/A ↗3 earlier filings
May 18, 2022	Nov 4, 2022	$25,000,000fully sold	35	$714K	Debt, Securities on exerciseRule 506(b)	Form D ↗
Feb 25, 2021	Mar 12, 2021amended Mar 12, 2021	$35,000,010fully sold	21	$1.6M	EquityRule 506(b)	Form D/A ↗1 earlier filing
Sep 18, 2019	Oct 3, 2019	$37,423,356fully sold	10	$3.7M	EquityRule 506(b)	Form D ↗
Jul 31, 2018	Aug 14, 2018amended Dec 7, 2018	$9,375,000fully sold	31	$302K	EquityRule 506(b)	Form D/A ↗1 earlier filing
Total, five offerings		$376,798,366

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Paragon Biosciences Emalex Capital's Form D filed Jul 8, 2025.

Patrick Morris

Executive Vice President and Secretary

Also a president, secretary and general counsel, director at CIRC Biosciences, a director at Castle Creek Biosciences and an executive officer and director at Evozyne.

Jeffrey Aronin

Director

Also a director at CIRC Biosciences and Castle Creek Biosciences and a chairman and director at Evozyne.

Antonio Gracias

Director

Also a director at CIRC Biosciences, Castle Creek Biosciences and Evozyne.

Eric Messner

Executive officer and director

Ricky Sun

Director

Jeffrey Dayno

Director